Business Wire

  1. Opna Bio Receives Orphan Drug Designation For OPN-6602, An Oral EP300/CBP Bromodomain Inhibitor, For Multiple Myeloma 2/12/2025

    Opna Bio, a clinical-stage biopharmaceutical company focused on the discovery and development of novel oncology therapeutics, announced today that the FDA has granted orphan drug designation (ODD) to one of its lead programs, OPN-6602, for the treatment of multiple myeloma (MM).

  2. Alloy Therapeutics Establishes Multi-Year Collaboration With Pfizer To Develop New Antibody Discovery Platform 2/11/2025

    Alloy Therapeutics Inc. (“Alloy”), a biotechnology ecosystem company dedicated to democratizing access to cutting edge drug discovery technologies, announced today its latest strategic collaboration with Pfizer Inc., to develop a new platform that could enhance Pfizer’s ability to discover potent, specific, and effective antibodies against targets that are difficult to address with existing antibody discovery technologies.

  3. United Therapeutics Corporation Announces FDA Clearance Of Its Investigational New Drug Application For The Ukidney Xenotransplantation Clinical Trial 2/3/2025

    United Therapeutics Corporation a public benefit corporation, today announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug application (IND) to initiate a clinical study of the company’s investigational UKidney derived from a 10 gene-edited source pig.

  4. BioStrand, ImmunoPrecise Antibodies' Subsidiary, Announces Immediate Commercial Offering Of Groundbreaking Software With Customizable Interface For AI-Driven Drug Discovery 6/10/2024

    ImmunoPrecise Antibodies Ltd. (“ImmunoPrecise” or “IPA” or the “Company”), a leader in AI-driven biotherapeutic research and technology, today announces the commercial release of LENSai API, hereafter referred to as the ‘software’, by its subsidiary, BioStrand. This advanced AI-driven software solution is available immediately.

  5. Every Cure Deploys BioPhy's Artificial Intelligence Platform To Accelerate Its Mission Of Repurposing Drugs For Untreated Diseases 4/30/2024

    BioPhy, an innovative AI drug development company, today announced a partnership with Every Cure, a nonprofit initiative on a mission to unlock the full potential of existing medicines to treat every disease and every patient they possibly can.

  6. X-Chem Acquires Glamorous AI — Immediately Creating A Leader In DEL-Powered AI Solutions 10/28/2021

    X-Chem, the pioneer of DNA-encoded library (DEL) technology and a recognized leader in generating actionable results to drive small molecule drug discovery, today announced the acquisition of Glamorous AI, a leader in artificial intelligence (AI) solutions for drug discovery.

  7. Pfizer Establishes Precision Medicine Research Collaboration With Medco 11/1/2011
    Pfizer Inc. (NYSE: PFE) announced recently that it has established a research collaboration with Medco Health Solutions, Inc. and its wholly owned subsidiary, United BioSource Corporation (UBC), aimed at more effectively matching patients with treatments that will benefit them the most, thereby improving patient outcomes
  8. Spectrum Pharmaceuticals To Present At The Rodman & Renshaw 10th Annual Global Healthcare Investment Conference 11/5/2008
    Spectrum Pharmaceuticals, Inc., announced today that an overview of the Company’s business strategy will be presented at the Rodman & Renshaw Annual 10th Annual Global Healthcare Investment Conference, on Tuesday, November 11, 2008, at 12:00 p.m. Eastern
  9. AgilityBio And Advinus Announce Partnership To Introduce Digital Pathology Services In Pre Clinical Research 11/5/2008
    AgilityBio, a division of BioImagene Inc, and Advinus Therapeutics, a TATA enterprise, announced a partnership that will enable providing imaging services in conjunction with preclinical development services offered by Advinus
  10. Progenics Selects Small-Molecule Hepatitis C Drug Candidate For Clinical Development 11/4/2008
    Progenics Pharmaceuticals, Inc.,today announced the selection of a proprietary small-molecule drug candidate, designated PRO 206, for clinical development as a treatment of hepatitis C virus (HCV) infection